nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Methoxsalen—psoriasis	0.096	0.129	CbGbCtD
Nevirapine—CYP3A5—Beclomethasone—psoriasis	0.071	0.0956	CbGbCtD
Nevirapine—CYP1A2—Clobetasol propionate—psoriasis	0.0697	0.0939	CbGbCtD
Nevirapine—CYP2A6—Prednisolone—psoriasis	0.0467	0.0628	CbGbCtD
Nevirapine—CYP2B6—Cholecalciferol—psoriasis	0.0414	0.0557	CbGbCtD
Nevirapine—CYP1A2—Methoxsalen—psoriasis	0.0366	0.0493	CbGbCtD
Nevirapine—CYP2D6—Hydroxyurea—psoriasis	0.033	0.0444	CbGbCtD
Nevirapine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0283	0.0381	CbGbCtD
Nevirapine—CYP2A6—Dexamethasone—psoriasis	0.0275	0.037	CbGbCtD
Nevirapine—CYP3A4—Calcitriol—psoriasis	0.0247	0.0332	CbGbCtD
Nevirapine—CYP3A5—Hydrocortisone—psoriasis	0.0227	0.0305	CbGbCtD
Nevirapine—CYP2C9—Cholecalciferol—psoriasis	0.0219	0.0294	CbGbCtD
Nevirapine—CYP3A5—Cyclosporine—psoriasis	0.0214	0.0288	CbGbCtD
Nevirapine—CYP2D6—Cholecalciferol—psoriasis	0.02	0.0269	CbGbCtD
Nevirapine—CYP3A4—Methoxsalen—psoriasis	0.0192	0.0258	CbGbCtD
Nevirapine—CYP2B6—Dexamethasone—psoriasis	0.0179	0.0241	CbGbCtD
Nevirapine—CYP2C9—Cyclosporine—psoriasis	0.0144	0.0193	CbGbCtD
Nevirapine—CYP3A5—Dexamethasone—psoriasis	0.0141	0.019	CbGbCtD
Nevirapine—CYP2D6—Cyclosporine—psoriasis	0.0131	0.0177	CbGbCtD
Nevirapine—CYP3A4—Cholecalciferol—psoriasis	0.0127	0.0171	CbGbCtD
Nevirapine—CYP3A4—Mycophenolate mofetil—psoriasis	0.011	0.0148	CbGbCtD
Nevirapine—CYP3A4—Triamcinolone—psoriasis	0.011	0.0148	CbGbCtD
Nevirapine—CYP2C9—Dexamethasone—psoriasis	0.00946	0.0127	CbGbCtD
Nevirapine—CYP3A4—Betamethasone—psoriasis	0.00945	0.0127	CbGbCtD
Nevirapine—CYP3A4—Prednisolone—psoriasis	0.00933	0.0126	CbGbCtD
Nevirapine—CYP3A4—Hydrocortisone—psoriasis	0.00884	0.0119	CbGbCtD
Nevirapine—CYP3A4—Prednisone—psoriasis	0.00881	0.0119	CbGbCtD
Nevirapine—CYP2D6—Dexamethasone—psoriasis	0.00865	0.0116	CbGbCtD
Nevirapine—CYP3A4—Cyclosporine—psoriasis	0.00835	0.0112	CbGbCtD
Nevirapine—CYP3A4—Dexamethasone—psoriasis	0.0055	0.00741	CbGbCtD
Nevirapine—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00273	0.0806	CbGpPWpGaD
Nevirapine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00221	0.065	CbGpPWpGaD
Nevirapine—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.0017	0.05	CbGpPWpGaD
Nevirapine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00153	0.0452	CbGpPWpGaD
Nevirapine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00152	0.0448	CbGpPWpGaD
Nevirapine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00143	0.0422	CbGpPWpGaD
Nevirapine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00137	0.0403	CbGpPWpGaD
Nevirapine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00134	0.0394	CbGpPWpGaD
Nevirapine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000951	0.028	CbGpPWpGaD
Nevirapine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000942	0.0278	CbGpPWpGaD
Nevirapine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000805	0.0237	CbGpPWpGaD
Nevirapine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000704	0.0207	CbGpPWpGaD
Nevirapine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000695	0.0205	CbGpPWpGaD
Nevirapine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000622	0.0183	CbGpPWpGaD
Nevirapine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000571	0.0168	CbGpPWpGaD
Nevirapine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000568	0.0167	CbGpPWpGaD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00056	0.0165	CbGpPWpGaD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000555	0.0164	CbGpPWpGaD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000548	0.0161	CbGpPWpGaD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00046	0.0136	CbGpPWpGaD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00045	0.0133	CbGpPWpGaD
Nevirapine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000441	0.013	CbGpPWpGaD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000395	0.0116	CbGpPWpGaD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000391	0.0115	CbGpPWpGaD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00039	0.0115	CbGpPWpGaD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000386	0.0114	CbGpPWpGaD
Nevirapine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000334	0.00985	CbGpPWpGaD
Nevirapine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00033	0.00973	CbGpPWpGaD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00032	0.00943	CbGpPWpGaD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000317	0.00935	CbGpPWpGaD
Nevirapine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000303	0.00893	CbGpPWpGaD
Nevirapine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000292	0.00861	CbGpPWpGaD
Nevirapine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000281	0.00829	CbGpPWpGaD
Nevirapine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000271	0.00799	CbGpPWpGaD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000261	0.00769	CbGpPWpGaD
Nevirapine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000258	0.00761	CbGpPWpGaD
Nevirapine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000255	0.00752	CbGpPWpGaD
Nevirapine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000255	0.00751	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000245	0.00721	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000241	0.00711	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000239	0.00704	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000236	0.00695	CbGpPWpGaD
Nevirapine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000209	0.00617	CbGpPWpGaD
Nevirapine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000206	0.00608	CbGpPWpGaD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000182	0.00536	CbGpPWpGaD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00018	0.0053	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.00017	0.00501	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000169	0.00497	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000169	0.00497	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000168	0.00494	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000166	0.0049	CbGpPWpGaD
Nevirapine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000165	0.00486	CbGpPWpGaD
Nevirapine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000164	0.00483	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00016	0.00473	CbGpPWpGaD
Nevirapine—Rash—Hydroxyurea—psoriasis	0.000156	0.000698	CcSEcCtD
Nevirapine—Erythema—Betamethasone—psoriasis	0.000156	0.000698	CcSEcCtD
Nevirapine—Erythema—Dexamethasone—psoriasis	0.000156	0.000698	CcSEcCtD
Nevirapine—Anorexia—Mycophenolate mofetil—psoriasis	0.000156	0.000698	CcSEcCtD
Nevirapine—Dermatitis—Hydroxyurea—psoriasis	0.000156	0.000698	CcSEcCtD
Nevirapine—Myalgia—Hydrocortisone—psoriasis	0.000155	0.000696	CcSEcCtD
Nevirapine—Malaise—Triamcinolone—psoriasis	0.000155	0.000694	CcSEcCtD
Nevirapine—Headache—Hydroxyurea—psoriasis	0.000155	0.000694	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000154	0.000691	CcSEcCtD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000154	0.00453	CbGpPWpGaD
Nevirapine—Discomfort—Hydrocortisone—psoriasis	0.000154	0.000687	CcSEcCtD
Nevirapine—Connective tissue disorder—Prednisone—psoriasis	0.000153	0.000686	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000153	0.000684	CcSEcCtD
Nevirapine—Oedema—Prednisolone—psoriasis	0.000153	0.000683	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisolone—psoriasis	0.000153	0.000683	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—psoriasis	0.000152	0.000682	CcSEcCtD
Nevirapine—Paraesthesia—Cyclosporine—psoriasis	0.000151	0.000674	CcSEcCtD
Nevirapine—Somnolence—Cyclosporine—psoriasis	0.000149	0.000667	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000149	0.000667	CcSEcCtD
Nevirapine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000149	0.000667	CcSEcCtD
Nevirapine—Oedema—Hydrocortisone—psoriasis	0.000149	0.000667	CcSEcCtD
Nevirapine—Asthenia—Mycophenolic acid—psoriasis	0.000149	0.000665	CcSEcCtD
Nevirapine—Nausea—Hydroxyurea—psoriasis	0.000147	0.000658	CcSEcCtD
Nevirapine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000147	0.000657	CcSEcCtD
Nevirapine—Pruritus—Mycophenolic acid—psoriasis	0.000147	0.000656	CcSEcCtD
Nevirapine—Myalgia—Triamcinolone—psoriasis	0.000146	0.000655	CcSEcCtD
Nevirapine—Nervous system disorder—Hydrocortisone—psoriasis	0.000146	0.000654	CcSEcCtD
Nevirapine—Decreased appetite—Cyclosporine—psoriasis	0.000146	0.000652	CcSEcCtD
Nevirapine—Somnolence—Mycophenolate mofetil—psoriasis	0.000145	0.000651	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000145	0.000648	CcSEcCtD
Nevirapine—Skin disorder—Hydrocortisone—psoriasis	0.000145	0.000648	CcSEcCtD
Nevirapine—Ill-defined disorder—Betamethasone—psoriasis	0.000145	0.000648	CcSEcCtD
Nevirapine—Ill-defined disorder—Dexamethasone—psoriasis	0.000145	0.000648	CcSEcCtD
Nevirapine—Discomfort—Triamcinolone—psoriasis	0.000145	0.000647	CcSEcCtD
Nevirapine—Fatigue—Cyclosporine—psoriasis	0.000145	0.000647	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000144	0.000645	CcSEcCtD
Nevirapine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000144	0.00424	CbGpPWpGaD
Nevirapine—Pain—Cyclosporine—psoriasis	0.000143	0.000642	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—psoriasis	0.000143	0.000639	CcSEcCtD
Nevirapine—Angioedema—Betamethasone—psoriasis	0.000143	0.000638	CcSEcCtD
Nevirapine—Angioedema—Dexamethasone—psoriasis	0.000143	0.000638	CcSEcCtD
Nevirapine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000142	0.000636	CcSEcCtD
Nevirapine—Anorexia—Hydrocortisone—psoriasis	0.000142	0.000636	CcSEcCtD
Nevirapine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000142	0.00419	CbGpPWpGaD
Nevirapine—Diarrhoea—Mycophenolic acid—psoriasis	0.000142	0.000635	CcSEcCtD
Nevirapine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000142	0.00418	CbGpPWpGaD
Nevirapine—Conjunctivitis—Methotrexate—psoriasis	0.000141	0.000632	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000141	0.000632	CcSEcCtD
Nevirapine—Immune system disorder—Prednisone—psoriasis	0.000141	0.000631	CcSEcCtD
Nevirapine—Malaise—Dexamethasone—psoriasis	0.000141	0.000629	CcSEcCtD
Nevirapine—Malaise—Betamethasone—psoriasis	0.000141	0.000629	CcSEcCtD
Nevirapine—Anaphylactic shock—Triamcinolone—psoriasis	0.00014	0.000628	CcSEcCtD
Nevirapine—Oedema—Triamcinolone—psoriasis	0.00014	0.000628	CcSEcCtD
Nevirapine—Pain—Mycophenolate mofetil—psoriasis	0.00014	0.000626	CcSEcCtD
Nevirapine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.00014	0.00411	CbGpPWpGaD
Nevirapine—Feeling abnormal—Cyclosporine—psoriasis	0.000138	0.000618	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—psoriasis	0.000137	0.000615	CcSEcCtD
Nevirapine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000137	0.000614	CcSEcCtD
Nevirapine—Paraesthesia—Prednisolone—psoriasis	0.000137	0.000613	CcSEcCtD
Nevirapine—Erythema—Prednisone—psoriasis	0.000136	0.000608	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000136	0.000608	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—psoriasis	0.000136	0.000607	CcSEcCtD
Nevirapine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000135	0.000603	CcSEcCtD
Nevirapine—Paraesthesia—Hydrocortisone—psoriasis	0.000134	0.000599	CcSEcCtD
Nevirapine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000134	0.000598	CcSEcCtD
Nevirapine—Urticaria—Cyclosporine—psoriasis	0.000133	0.000596	CcSEcCtD
Nevirapine—Myalgia—Betamethasone—psoriasis	0.000133	0.000594	CcSEcCtD
Nevirapine—Myalgia—Dexamethasone—psoriasis	0.000133	0.000594	CcSEcCtD
Nevirapine—Body temperature increased—Cyclosporine—psoriasis	0.000133	0.000593	CcSEcCtD
Nevirapine—Abdominal pain—Cyclosporine—psoriasis	0.000133	0.000593	CcSEcCtD
Nevirapine—Vomiting—Mycophenolic acid—psoriasis	0.000132	0.00059	CcSEcCtD
Nevirapine—Discomfort—Dexamethasone—psoriasis	0.000131	0.000587	CcSEcCtD
Nevirapine—Discomfort—Betamethasone—psoriasis	0.000131	0.000587	CcSEcCtD
Nevirapine—Rash—Mycophenolic acid—psoriasis	0.000131	0.000585	CcSEcCtD
Nevirapine—Dermatitis—Mycophenolic acid—psoriasis	0.000131	0.000584	CcSEcCtD
Nevirapine—Pain—Prednisolone—psoriasis	0.00013	0.000584	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—psoriasis	0.00013	0.000584	CcSEcCtD
Nevirapine—Urticaria—Mycophenolate mofetil—psoriasis	0.00013	0.000581	CcSEcCtD
Nevirapine—Headache—Mycophenolic acid—psoriasis	0.00013	0.000581	CcSEcCtD
Nevirapine—Decreased appetite—Hydrocortisone—psoriasis	0.00013	0.00058	CcSEcCtD
Nevirapine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000129	0.000579	CcSEcCtD
Nevirapine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000129	0.000579	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000129	0.000576	CcSEcCtD
Nevirapine—Fatigue—Hydrocortisone—psoriasis	0.000128	0.000575	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000128	0.000572	CcSEcCtD
Nevirapine—Pain—Hydrocortisone—psoriasis	0.000127	0.00057	CcSEcCtD
Nevirapine—Oedema—Dexamethasone—psoriasis	0.000127	0.00057	CcSEcCtD
Nevirapine—Anaphylactic shock—Betamethasone—psoriasis	0.000127	0.00057	CcSEcCtD
Nevirapine—Oedema—Betamethasone—psoriasis	0.000127	0.00057	CcSEcCtD
Nevirapine—Anaphylactic shock—Dexamethasone—psoriasis	0.000127	0.00057	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisone—psoriasis	0.000126	0.000564	CcSEcCtD
Nevirapine—Paraesthesia—Triamcinolone—psoriasis	0.000126	0.000564	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisolone—psoriasis	0.000126	0.000563	CcSEcCtD
Nevirapine—Anaemia—Prednisone—psoriasis	0.000126	0.000562	CcSEcCtD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000125	0.00369	CbGpPWpGaD
Nevirapine—Nervous system disorder—Dexamethasone—psoriasis	0.000125	0.000559	CcSEcCtD
Nevirapine—Nervous system disorder—Betamethasone—psoriasis	0.000125	0.000559	CcSEcCtD
Nevirapine—Thrombocytopenia—Dexamethasone—psoriasis	0.000125	0.000558	CcSEcCtD
Nevirapine—Thrombocytopenia—Betamethasone—psoriasis	0.000125	0.000558	CcSEcCtD
Nevirapine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000124	0.00366	CbGpPWpGaD
Nevirapine—Angioedema—Prednisone—psoriasis	0.000124	0.000555	CcSEcCtD
Nevirapine—Hypersensitivity—Cyclosporine—psoriasis	0.000124	0.000553	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—psoriasis	0.000123	0.000552	CcSEcCtD
Nevirapine—Nausea—Mycophenolic acid—psoriasis	0.000123	0.000551	CcSEcCtD
Nevirapine—Feeling abnormal—Hydrocortisone—psoriasis	0.000123	0.000549	CcSEcCtD
Nevirapine—Malaise—Prednisone—psoriasis	0.000122	0.000548	CcSEcCtD
Nevirapine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000122	0.000545	CcSEcCtD
Nevirapine—Anorexia—Betamethasone—psoriasis	0.000121	0.000543	CcSEcCtD
Nevirapine—Anorexia—Dexamethasone—psoriasis	0.000121	0.000543	CcSEcCtD
Nevirapine—Urticaria—Prednisolone—psoriasis	0.000121	0.000542	CcSEcCtD
Nevirapine—Fatigue—Triamcinolone—psoriasis	0.000121	0.000541	CcSEcCtD
Nevirapine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00012	0.000539	CcSEcCtD
Nevirapine—Asthenia—Cyclosporine—psoriasis	0.00012	0.000538	CcSEcCtD
Nevirapine—Pain—Triamcinolone—psoriasis	0.00012	0.000537	CcSEcCtD
Nevirapine—Pruritus—Cyclosporine—psoriasis	0.000119	0.000531	CcSEcCtD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000119	0.00349	CbGpPWpGaD
Nevirapine—Urticaria—Hydrocortisone—psoriasis	0.000118	0.00053	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—psoriasis	0.000118	0.000527	CcSEcCtD
Nevirapine—Abdominal pain—Hydrocortisone—psoriasis	0.000118	0.000527	CcSEcCtD
Nevirapine—Body temperature increased—Hydrocortisone—psoriasis	0.000118	0.000527	CcSEcCtD
Nevirapine—Asthenia—Mycophenolate mofetil—psoriasis	0.000117	0.000525	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000116	0.000519	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000116	0.000519	CcSEcCtD
Nevirapine—Pruritus—Mycophenolate mofetil—psoriasis	0.000116	0.000518	CcSEcCtD
Nevirapine—Myalgia—Prednisone—psoriasis	0.000116	0.000518	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—psoriasis	0.000116	0.000518	CcSEcCtD
Nevirapine—Feeling abnormal—Triamcinolone—psoriasis	0.000116	0.000517	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000115	0.000514	CcSEcCtD
Nevirapine—Diarrhoea—Cyclosporine—psoriasis	0.000115	0.000513	CcSEcCtD
Nevirapine—Paraesthesia—Betamethasone—psoriasis	0.000114	0.000512	CcSEcCtD
Nevirapine—Paraesthesia—Dexamethasone—psoriasis	0.000114	0.000512	CcSEcCtD
Nevirapine—Discomfort—Prednisone—psoriasis	0.000114	0.000511	CcSEcCtD
Nevirapine—Erythema—Methotrexate—psoriasis	0.000114	0.000508	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisolone—psoriasis	0.000112	0.000503	CcSEcCtD
Nevirapine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000112	0.000501	CcSEcCtD
Nevirapine—Urticaria—Triamcinolone—psoriasis	0.000111	0.000499	CcSEcCtD
Nevirapine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00328	CbGpPWpGaD
Nevirapine—Body temperature increased—Triamcinolone—psoriasis	0.000111	0.000496	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisone—psoriasis	0.000111	0.000496	CcSEcCtD
Nevirapine—Oedema—Prednisone—psoriasis	0.000111	0.000496	CcSEcCtD
Nevirapine—Decreased appetite—Betamethasone—psoriasis	0.000111	0.000495	CcSEcCtD
Nevirapine—Decreased appetite—Dexamethasone—psoriasis	0.000111	0.000495	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Betamethasone—psoriasis	0.00011	0.000492	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00011	0.000492	CcSEcCtD
Nevirapine—Hypersensitivity—Hydrocortisone—psoriasis	0.00011	0.000491	CcSEcCtD
Nevirapine—Fatigue—Dexamethasone—psoriasis	0.00011	0.000491	CcSEcCtD
Nevirapine—Fatigue—Betamethasone—psoriasis	0.00011	0.000491	CcSEcCtD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.00011	0.00323	CbGpPWpGaD
Nevirapine—Pain—Dexamethasone—psoriasis	0.000109	0.000487	CcSEcCtD
Nevirapine—Pain—Betamethasone—psoriasis	0.000109	0.000487	CcSEcCtD
Nevirapine—Nervous system disorder—Prednisone—psoriasis	0.000109	0.000487	CcSEcCtD
Nevirapine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000108	0.00319	CbGpPWpGaD
Nevirapine—Skin disorder—Prednisone—psoriasis	0.000108	0.000482	CcSEcCtD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000107	0.00316	CbGpPWpGaD
Nevirapine—Asthenia—Hydrocortisone—psoriasis	0.000107	0.000478	CcSEcCtD
Nevirapine—Vomiting—Cyclosporine—psoriasis	0.000107	0.000477	CcSEcCtD
Nevirapine—Rash—Cyclosporine—psoriasis	0.000106	0.000473	CcSEcCtD
Nevirapine—Anorexia—Prednisone—psoriasis	0.000106	0.000473	CcSEcCtD
Nevirapine—Dermatitis—Cyclosporine—psoriasis	0.000106	0.000473	CcSEcCtD
Nevirapine—Pruritus—Hydrocortisone—psoriasis	0.000105	0.000472	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—psoriasis	0.000105	0.000471	CcSEcCtD
Nevirapine—Headache—Cyclosporine—psoriasis	0.000105	0.00047	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—psoriasis	0.000105	0.00047	CcSEcCtD
Nevirapine—Feeling abnormal—Dexamethasone—psoriasis	0.000105	0.000469	CcSEcCtD
Nevirapine—Feeling abnormal—Betamethasone—psoriasis	0.000105	0.000469	CcSEcCtD
Nevirapine—Gastrointestinal pain—Betamethasone—psoriasis	0.000104	0.000466	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000104	0.000466	CcSEcCtD
Nevirapine—Vomiting—Mycophenolate mofetil—psoriasis	0.000104	0.000465	CcSEcCtD
Nevirapine—Hypersensitivity—Triamcinolone—psoriasis	0.000103	0.000463	CcSEcCtD
Nevirapine—Rash—Mycophenolate mofetil—psoriasis	0.000103	0.000461	CcSEcCtD
Nevirapine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000103	0.000461	CcSEcCtD
Nevirapine—Headache—Mycophenolate mofetil—psoriasis	0.000102	0.000459	CcSEcCtD
Nevirapine—Malaise—Methotrexate—psoriasis	0.000102	0.000458	CcSEcCtD
Nevirapine—Diarrhoea—Hydrocortisone—psoriasis	0.000102	0.000456	CcSEcCtD
Nevirapine—Urticaria—Betamethasone—psoriasis	0.000101	0.000453	CcSEcCtD
Nevirapine—Urticaria—Dexamethasone—psoriasis	0.000101	0.000453	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000101	0.000452	CcSEcCtD
Nevirapine—Asthenia—Triamcinolone—psoriasis	0.000101	0.00045	CcSEcCtD
Nevirapine—Abdominal pain—Betamethasone—psoriasis	0.000101	0.00045	CcSEcCtD
Nevirapine—Abdominal pain—Dexamethasone—psoriasis	0.000101	0.00045	CcSEcCtD
Nevirapine—Body temperature increased—Betamethasone—psoriasis	0.000101	0.00045	CcSEcCtD
Nevirapine—Body temperature increased—Dexamethasone—psoriasis	0.000101	0.00045	CcSEcCtD
Nevirapine—Nausea—Cyclosporine—psoriasis	9.96e-05	0.000446	CcSEcCtD
Nevirapine—Paraesthesia—Prednisone—psoriasis	9.95e-05	0.000445	CcSEcCtD
Nevirapine—Pruritus—Triamcinolone—psoriasis	9.93e-05	0.000444	CcSEcCtD
Nevirapine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.8e-05	0.00289	CbGpPWpGaD
Nevirapine—Nausea—Mycophenolate mofetil—psoriasis	9.71e-05	0.000435	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—psoriasis	9.66e-05	0.000433	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—psoriasis	9.66e-05	0.000433	CcSEcCtD
Nevirapine—Decreased appetite—Prednisone—psoriasis	9.64e-05	0.000431	CcSEcCtD
Nevirapine—Rash—Prednisolone—psoriasis	9.62e-05	0.00043	CcSEcCtD
Nevirapine—Dermatitis—Prednisolone—psoriasis	9.61e-05	0.00043	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.6e-05	0.00043	CcSEcCtD
Nevirapine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.59e-05	0.00283	CbGpPWpGaD
Nevirapine—Fatigue—Prednisone—psoriasis	9.56e-05	0.000428	CcSEcCtD
Nevirapine—Headache—Prednisolone—psoriasis	9.56e-05	0.000428	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—psoriasis	9.55e-05	0.000427	CcSEcCtD
Nevirapine—Vomiting—Hydrocortisone—psoriasis	9.47e-05	0.000424	CcSEcCtD
Nevirapine—Rash—Hydrocortisone—psoriasis	9.39e-05	0.00042	CcSEcCtD
Nevirapine—Dermatitis—Hydrocortisone—psoriasis	9.39e-05	0.00042	CcSEcCtD
Nevirapine—Headache—Hydrocortisone—psoriasis	9.33e-05	0.000418	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—psoriasis	9.27e-05	0.000415	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisone—psoriasis	9.14e-05	0.000409	CcSEcCtD
Nevirapine—Asthenia—Dexamethasone—psoriasis	9.13e-05	0.000409	CcSEcCtD
Nevirapine—Asthenia—Betamethasone—psoriasis	9.13e-05	0.000409	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—psoriasis	9.09e-05	0.000407	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—psoriasis	9.07e-05	0.000406	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—psoriasis	9.07e-05	0.000406	CcSEcCtD
Nevirapine—Nausea—Prednisolone—psoriasis	9.06e-05	0.000406	CcSEcCtD
Nevirapine—Pruritus—Betamethasone—psoriasis	9.01e-05	0.000403	CcSEcCtD
Nevirapine—Pruritus—Dexamethasone—psoriasis	9.01e-05	0.000403	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—psoriasis	9e-05	0.000403	CcSEcCtD
Nevirapine—Vomiting—Triamcinolone—psoriasis	8.92e-05	0.000399	CcSEcCtD
Nevirapine—Nausea—Hydrocortisone—psoriasis	8.85e-05	0.000396	CcSEcCtD
Nevirapine—Rash—Triamcinolone—psoriasis	8.85e-05	0.000396	CcSEcCtD
Nevirapine—Dermatitis—Triamcinolone—psoriasis	8.84e-05	0.000396	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—psoriasis	8.83e-05	0.000395	CcSEcCtD
Nevirapine—Urticaria—Prednisone—psoriasis	8.81e-05	0.000394	CcSEcCtD
Nevirapine—Headache—Triamcinolone—psoriasis	8.79e-05	0.000393	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—psoriasis	8.76e-05	0.000392	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—psoriasis	8.76e-05	0.000392	CcSEcCtD
Nevirapine—Diarrhoea—Dexamethasone—psoriasis	8.71e-05	0.00039	CcSEcCtD
Nevirapine—Diarrhoea—Betamethasone—psoriasis	8.71e-05	0.00039	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—psoriasis	8.44e-05	0.000378	CcSEcCtD
Nevirapine—Nausea—Triamcinolone—psoriasis	8.33e-05	0.000373	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—psoriasis	8.32e-05	0.000372	CcSEcCtD
Nevirapine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	8.3e-05	0.00245	CbGpPWpGaD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.26e-05	0.00244	CbGpPWpGaD
Nevirapine—Somnolence—Methotrexate—psoriasis	8.24e-05	0.000369	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisone—psoriasis	8.17e-05	0.000366	CcSEcCtD
Nevirapine—Vomiting—Dexamethasone—psoriasis	8.09e-05	0.000362	CcSEcCtD
Nevirapine—Vomiting—Betamethasone—psoriasis	8.09e-05	0.000362	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—psoriasis	8.05e-05	0.00036	CcSEcCtD
Nevirapine—Rash—Betamethasone—psoriasis	8.03e-05	0.000359	CcSEcCtD
Nevirapine—Rash—Dexamethasone—psoriasis	8.03e-05	0.000359	CcSEcCtD
Nevirapine—Dermatitis—Betamethasone—psoriasis	8.02e-05	0.000359	CcSEcCtD
Nevirapine—Dermatitis—Dexamethasone—psoriasis	8.02e-05	0.000359	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—psoriasis	8e-05	0.000358	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—psoriasis	7.99e-05	0.000357	CcSEcCtD
Nevirapine—Headache—Betamethasone—psoriasis	7.97e-05	0.000357	CcSEcCtD
Nevirapine—Headache—Dexamethasone—psoriasis	7.97e-05	0.000357	CcSEcCtD
Nevirapine—Asthenia—Prednisone—psoriasis	7.95e-05	0.000356	CcSEcCtD
Nevirapine—Pain—Methotrexate—psoriasis	7.92e-05	0.000355	CcSEcCtD
Nevirapine—Pruritus—Prednisone—psoriasis	7.84e-05	0.000351	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—psoriasis	7.64e-05	0.000342	CcSEcCtD
Nevirapine—Diarrhoea—Prednisone—psoriasis	7.59e-05	0.000339	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—psoriasis	7.58e-05	0.000339	CcSEcCtD
Nevirapine—Nausea—Dexamethasone—psoriasis	7.56e-05	0.000338	CcSEcCtD
Nevirapine—Nausea—Betamethasone—psoriasis	7.56e-05	0.000338	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—psoriasis	7.36e-05	0.000329	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—psoriasis	7.32e-05	0.000328	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—psoriasis	7.32e-05	0.000328	CcSEcCtD
Nevirapine—Vomiting—Prednisone—psoriasis	7.05e-05	0.000315	CcSEcCtD
Nevirapine—Rash—Prednisone—psoriasis	6.99e-05	0.000313	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—psoriasis	6.98e-05	0.000313	CcSEcCtD
Nevirapine—Headache—Prednisone—psoriasis	6.95e-05	0.000311	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.9e-05	0.00203	CbGpPWpGaD
Nevirapine—Hypersensitivity—Methotrexate—psoriasis	6.83e-05	0.000305	CcSEcCtD
Nevirapine—Asthenia—Methotrexate—psoriasis	6.65e-05	0.000297	CcSEcCtD
Nevirapine—Nausea—Prednisone—psoriasis	6.59e-05	0.000295	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—psoriasis	6.56e-05	0.000293	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—psoriasis	6.34e-05	0.000284	CcSEcCtD
Nevirapine—CYP2A6—Metabolism—NDUFA5—psoriasis	6.1e-05	0.0018	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.96e-05	0.00176	CbGpPWpGaD
Nevirapine—Vomiting—Methotrexate—psoriasis	5.89e-05	0.000264	CcSEcCtD
Nevirapine—Rash—Methotrexate—psoriasis	5.84e-05	0.000261	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—psoriasis	5.84e-05	0.000261	CcSEcCtD
Nevirapine—Headache—Methotrexate—psoriasis	5.8e-05	0.00026	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.74e-05	0.00169	CbGpPWpGaD
Nevirapine—Nausea—Methotrexate—psoriasis	5.5e-05	0.000246	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.21e-05	0.00154	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP2S1—psoriasis	5.18e-05	0.00153	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NDUFA5—psoriasis	4.92e-05	0.00145	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NDUFA5—psoriasis	4.81e-05	0.00142	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.47e-05	0.00132	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.47e-05	0.00132	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP2S1—psoriasis	4.18e-05	0.00123	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP2S1—psoriasis	4.09e-05	0.0012	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NDUFA5—psoriasis	3.42e-05	0.00101	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NDUFA5—psoriasis	3.39e-05	0.000999	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.16e-05	0.000931	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.91e-05	0.000857	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.9e-05	0.000854	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.88e-05	0.000849	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.7e-05	0.000796	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CARM1—psoriasis	2.53e-05	0.000746	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP2S1—psoriasis	2.46e-05	0.000726	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.24e-05	0.000659	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CARM1—psoriasis	2.04e-05	0.000602	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CARM1—psoriasis	2e-05	0.000588	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.9e-05	0.00056	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CAT—psoriasis	1.56e-05	0.000459	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.51e-05	0.000445	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CARM1—psoriasis	1.42e-05	0.000418	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CARM1—psoriasis	1.41e-05	0.000415	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.32e-05	0.000388	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.29e-05	0.00038	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CAT—psoriasis	1.26e-05	0.00037	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CAT—psoriasis	1.23e-05	0.000362	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—APOE—psoriasis	1.21e-05	0.000357	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CARM1—psoriasis	1.2e-05	0.000354	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.12e-05	0.000331	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PPARG—psoriasis	1.05e-05	0.000311	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—APOE—psoriasis	9.76e-06	0.000288	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—APOE—psoriasis	9.54e-06	0.000281	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CARM1—psoriasis	9.28e-06	0.000274	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CAT—psoriasis	8.73e-06	0.000257	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CAT—psoriasis	8.66e-06	0.000255	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PPARG—psoriasis	8.5e-06	0.000251	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PPARG—psoriasis	8.31e-06	0.000245	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CAT—psoriasis	7.4e-06	0.000218	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—APOE—psoriasis	6.78e-06	0.0002	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—APOE—psoriasis	6.73e-06	0.000198	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PPARG—psoriasis	5.91e-06	0.000174	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PPARG—psoriasis	5.86e-06	0.000173	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—APOE—psoriasis	5.75e-06	0.000169	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CAT—psoriasis	5.71e-06	0.000168	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PPARG—psoriasis	5.01e-06	0.000148	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—APOE—psoriasis	4.44e-06	0.000131	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PPARG—psoriasis	3.86e-06	0.000114	CbGpPWpGaD
